Would you move to a venetoclax-based regimen for a patient with pentarefractory MM and t(11;14) translocation, previously treated with bortezomib and carfilzomib?

If so, venetoclax/dexamethasone by itself or do you include a PI?

Answer from: Medical Oncologist at Academic Institution

To clarify what is meant by pentarefractory, we are referring to a situation where a patient's myeloma has proven resistant to two proteasome inhibitors (bortezomib, carfilzomib), two IMiDs (lenalidomide/pomalidomide), and an anti-CD38 monoclonal antibody (daratumumab/isatuximab). There are not many...

Comments

Medical Oncologist at University of Washington, Fred Hutchinson Cancer Research Center
Very helpful and well written as always - thank yo...

Answer from: Medical Oncologist at Community Practice

I like the important point about verifying that t(11;14) is the bulk of the patient's relapsed myeloma acknowledging a patchy & potentially diverse marrow. I also appreciate caution regarding CYP3A4 interactions, although anti fungal prophylaxis is not common in myeloma. Finally, I agree with Ve...

Comments

Medical Oncologist at University of Washington, Fred Hutchinson Cancer Research Center
Could not agree more, and I had not heard of Noxa ...

Please select the option that best describes you:

Would you move to a venetoclax-based regimen for a patient with pentarefractory MM and t(11;14) translocation, previously treated with bortezomib and carfilzomib?

Related Questions